Description
GLP-1 receptor agonist for type 2 diabetes and obesity
Semaglutide is a synthetic GLP-1 receptor agonist, a glucagon-like peptide-1 analog that mimics the effects of naturally occurring GLP-1. Enhances insulin secretion in response to meals while suppressing glucagon release, leading to improved glycemic control. Delays gastric emptying and acts on appetite centers in the brain, contributing to reduced food intake and significant weight loss. Effective in reducing HbA1c levels and supporting sustained metabolic health improvement.
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728 | DOI: 10.1001/jama.2021.3224
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID: 35441470 | DOI: 10.1111/dom.14725
